Compare NUS & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUS | FATE |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.4M | 260.0M |
| IPO Year | 1996 | 2013 |
| Metric | NUS | FATE |
|---|---|---|
| Price | $4.22 | $1.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $5.72 |
| AVG Volume (30 Days) | 445.0K | ★ 1.2M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 5.85% | N/A |
| EPS Growth | ★ 207.80 | 29.88 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,176,718,000.00 | $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.10 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 48.98 | N/A |
| 52 Week Low | $4.10 | $0.95 |
| 52 Week High | $11.67 | $3.23 |
| Indicator | NUS | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 37.29 | 40.07 |
| Support Level | N/A | $1.78 |
| Resistance Level | $4.94 | $2.19 |
| Average True Range (ATR) | 0.25 | 0.12 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 19.48 | 23.81 |
Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.